Format

Send to

Choose Destination
See comment in PubMed Commons below
J Transl Med. 2011 Mar 4;9:25. doi: 10.1186/1479-5876-9-25.

Intravenous ascorbic acid to prevent and treat cancer-associated sepsis?

Author information

1
Department of Orthomolecular Studies, Riordan Clinic, 3100 N Hillside, Wichita, Kansas 67210, USA.

Abstract

The history of ascorbic acid (AA) and cancer has been marked with controversy. Clinical studies evaluating AA in cancer outcome continue to the present day. However, the wealth of data suggesting that AA may be highly beneficial in addressing cancer-associated inflammation, particularly progression to systemic inflammatory response syndrome (SIRS) and multi organ failure (MOF), has been largely overlooked. Patients with advanced cancer are generally deficient in AA. Once these patients develop septic symptoms, a further decrease in ascorbic acid levels occurs. Given the known role of ascorbate in: a) maintaining endothelial and suppression of inflammatory markers; b) protection from sepsis in animal models; and c) direct antineoplastic effects, we propose the use of ascorbate as an adjuvant to existing modalities in the treatment and prevention of cancer-associated sepsis.

PMID:
21375761
PMCID:
PMC3061919
DOI:
10.1186/1479-5876-9-25
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Support Center